<p>Oncobiologics（纳斯达克代码：OTLK - 获取免费报告）预计将在 2025 年 12 月 26 日星期五市场开盘前发布其 2025 年第四季度财报。分析师预计 Oncobiologics 将发布每股收益（$0.23）和该季度收入为 584.60 万美元。投资者可以查看公司即将发布的 2025 年第四季度财报摘要页面，以获取关于定于 2025 年 12 月 24 日下午 4:00（东部时间）电话会议的最新信息。</p>
<p>获取 <strong>Oncobiologics</strong> 警报：</p>
<h2>Oncobiologics 股价下跌 8.8%</h2>
<ul>
<li>3 只被压制的制药股，具备上涨催化剂</li>
</ul>
<p>OTLK 股票在星期五开盘时为 $2.07。该股票的市值为 9195 万美元，市盈率为 -3.63，贝塔值为 0.17。Oncobiologics 的十二个月最低价为 $0.79，最高价为 $3.39。公司的 50 日移动平均线为 $1.62，200 日移动平均线为 $1.66。</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师对该公司发布了报告。Guggenheim 在 8 月 28 日的报告中将 Oncobiologics 的评级从 “买入” 下调至 “中性”。Weiss Ratings 在 12 月 8 日的研究报告中重新发布了 Oncobiologics 的 “卖出（d-）” 评级。Ascendiant Capital Markets 在 9 月 22 日的研究报告中将 Oncobiologics 的目标价从 $21.00 下调至 $8.00，并对该股票给予 “买入” 评级。Zacks Research 在 8 月 27 日的研究报告中将 Oncobiologics 的评级从 “强力买入” 下调至 “持有”。最后，HC Wainwright 在 9 月 30 日的研究报告中重申了 Oncobiologics 的 “中性” 评级。一位投资分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 $6.50。</p>
<ul>
<li>MarketBeat 周回顾 – 6/17 - 6/21</li>
</ul>
<p><strong>获取我们最新的 Oncobiologics 股票分析</strong></p>
<h2>机构投资者对 Oncobiologics 的看法</h2>
<p>几家机构投资者最近调整了对 OTLK 的持股。Russell Investments Group Ltd. 在第二季度将其在 Oncobiologics 的股份增加了 865.2%。Russell Investments Group Ltd. 现在拥有 24,477 股该公司的股票，价值 39,000 美元，此前在上个季度购买了 21,941 股。高盛集团在第一季度将其在 Oncobiologics 的持股增加了 74.1%。高盛集团现在拥有 103,524 股该公司的股票，价值 126,000 美元，此前在上个季度购买了 44,063 股。最后，AQR Capital Management LLC 在第一季度将其在 Oncobiologics 的持股增加了 42.7%。AQR Capital Management LLC 现在拥有 84,671 股该公司的股票，价值 103,000 美元，此前在上个季度购买了 25,351 股。对冲基金和其他机构投资者持有该公司 11.20% 的股票。</p>
<h2>关于 Oncobiologics</h2>
<p>（获取免费报告）</p>
<ul>
<li>Outlook Therapeutics：分析师预测股票上涨超过 500%</li>
</ul>
<p>Outlook Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，一种用于治疗湿性年龄相关性黄斑变性和其他视网膜疾病的贝伐单抗眼用制剂，目前处于第三阶段临床试验中。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Oncobiologics</li>
<li>风险承受能力，适合所有人的一刀切并不适用</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至$500</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>什么是分红成长股？简介</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Oncobiologics 吗？</h2>
<p>在考虑 Oncobiologics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Oncobiologics 并不在名单上。</p>
<p>虽然 Oncobiologics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

OTLK

<p>Oncobiologics（纳斯达克代码：OTLK）将于 12 月 26 日公布 2025 年第四季度财报，分析师预计每股亏损 0.23 美元，收入为 584.6 万美元。该公司的市值为 9195 万美元，近期分析师评级发生了变化，包括 Guggenheim 和 Zacks Research 的下调。机构投资者已调整其持股，Russell Investments 和高盛增加了其股份。该公司专注于开发用于眼科适应症的单克隆抗体</p>

<p>Oncobiologics (NASDAQ:OTLK - Get Free Report) is projected to release its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect Oncobiologics to post earnings of ($0.23) per share and revenue of $5.8460 million for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, December 24, 2025 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Oncobiologics（纳斯达克代码：OTLK - 获取免费报告）预计将在 2025 年 12 月 26 日星期五市场开盘前发布其 2025 年第四季度财报。分析师预计 Oncobiologics 将发布每股收益（$0.23）和该季度收入为 584.60 万美元。投资者可以查看公司即将发布的 2025 年第四季度财报摘要页面，以获取关于定于 2025 年 12 月 24 日下午 4:00（东部时间）电话会议的最新信息。</p>
</div><p>Get <strong>Oncobiologics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oncobiologics</strong> 警报：</p>
</div><h2>Oncobiologics Trading Down 8.8%</h2>
<div class="lb-trans"><h2>Oncobiologics 股价下跌 8.8%</h2>
</div><ul>
<li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被压制的制药股，具备上涨催化剂</li>
</ul>
</div><p>OTLK stock opened at $2.07 on Friday. The stock has a market cap of $91.95 million, a P/E ratio of -3.63 and a beta of 0.17. Oncobiologics has a twelve month low of $0.79 and a twelve month high of $3.39. The company's 50 day moving average is $1.62 and its two-hundred day moving average is $1.66.</p>
<div class="lb-trans"><p>OTLK 股票在星期五开盘时为 $2.07。该股票的市值为 9195 万美元，市盈率为 -3.63，贝塔值为 0.17。Oncobiologics 的十二个月最低价为 $0.79，最高价为 $3.39。公司的 50 日移动平均线为 $1.62，200 日移动平均线为 $1.66。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts have issued reports on the company. Guggenheim lowered Oncobiologics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Thursday, August 28th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Oncobiologics in a research report on Monday, December 8th. Ascendiant Capital Markets dropped their price target on Oncobiologics from $21.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, September 22nd. Zacks Research cut Oncobiologics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, August 27th. Finally, HC Wainwright restated a &#34;neutral&#34; rating on shares of Oncobiologics in a research report on Tuesday, September 30th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $6.50.</p>
<div class="lb-trans"><p>几位股票分析师对该公司发布了报告。Guggenheim 在 8 月 28 日的报告中将 Oncobiologics 的评级从 “买入” 下调至 “中性”。Weiss Ratings 在 12 月 8 日的研究报告中重新发布了 Oncobiologics 的 “卖出（d-）” 评级。Ascendiant Capital Markets 在 9 月 22 日的研究报告中将 Oncobiologics 的目标价从 $21.00 下调至 $8.00，并对该股票给予 “买入” 评级。Zacks Research 在 8 月 27 日的研究报告中将 Oncobiologics 的评级从 “强力买入” 下调至 “持有”。最后，HC Wainwright 在 9 月 30 日的研究报告中重申了 Oncobiologics 的 “中性” 评级。一位投资分析师对该股票给予了 “买入” 评级，四位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 $6.50。</p>
</div><ul>
<li>MarketBeat Week in Review – 6/17 - 6/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 6/17 - 6/21</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Oncobiologics</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Oncobiologics 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Oncobiologics</h2>
<div class="lb-trans"><h2>机构投资者对 Oncobiologics 的看法</h2>
</div><p>Several institutional investors have recently modified their holdings of OTLK. Russell Investments Group Ltd. increased its stake in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company's stock valued at $39,000 after purchasing an additional 21,941 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after purchasing an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对 OTLK 的持股。Russell Investments Group Ltd. 在第二季度将其在 Oncobiologics 的股份增加了 865.2%。Russell Investments Group Ltd. 现在拥有 24,477 股该公司的股票，价值 39,000 美元，此前在上个季度购买了 21,941 股。高盛集团在第一季度将其在 Oncobiologics 的持股增加了 74.1%。高盛集团现在拥有 103,524 股该公司的股票，价值 126,000 美元，此前在上个季度购买了 44,063 股。最后，AQR Capital Management LLC 在第一季度将其在 Oncobiologics 的持股增加了 42.7%。AQR Capital Management LLC 现在拥有 84,671 股该公司的股票，价值 103,000 美元，此前在上个季度购买了 25,351 股。对冲基金和其他机构投资者持有该公司 11.20% 的股票。</p>
</div><h2>About Oncobiologics</h2>
<div class="lb-trans"><h2>关于 Oncobiologics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Outlook Therapeutics：分析师预测股票上涨超过 500%</li>
</ul>
</div><p>Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.</p>
<div class="lb-trans"><p>Outlook Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，一种用于治疗湿性年龄相关性黄斑变性和其他视网膜疾病的贝伐单抗眼用制剂，目前处于第三阶段临床试验中。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Oncobiologics</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Oncobiologics</li>
<li>风险承受能力，适合所有人的一刀切并不适用</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至$500</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>什么是分红成长股？简介</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OTLK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oncobiologics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Oncobiologics 吗？</h2>
</div><p>Before you consider Oncobiologics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oncobiologics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncobiologics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Oncobiologics 并不在名单上。</p>
</div><p>While Oncobiologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oncobiologics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Oncobiologics（OTLK）预计将在周五宣布季度财报